Economic factors in of patients’ nonadherence to antidepressant treatment
- First Online:
Patients’ nonadherence to antidepressant treatment hampers cost and efficacy of depression-specific treatment. However, previous studies have failed to find consistent findings in economic effect on nonadherence and also failed to reach consensus in how to measure nonadherence to treatment. The study attempts to investigate income effect on nonadherence to selective serotonin reuptake inhibitors (SSRIs) treatment with clear definitions of nonadherence: self discontinuation of SSRIs (nonpersistence) and under-dose of SSRIs (noncompliance).
The study extracted data from the National Comorbidity Survey-Replication (NCS-R). The study sample (n = 280) includes adults between the ages of 18 and 64 who were diagnosed with Diagnostic Statistics Manual IV Major Depressive Episode (MDE) at some point during their lifetime and medicated with SSRIs in the past 12 months.
Just above poverty level of family income and no health insurance increased the risk of medication nonpersistence in SSRIs treatment. The study findings confirmed that African Americans were at higher risk of medication noncompliance than Whites (odds ratio, 4.53) and MDE comorbidity was positively associated with medication noncompliance (odds ratio, 4.25).
Low income level, combined with health insurance status, and race/ethnicity, predict nonadherence to antidepressant treatment. The study findings would help physicians and hospitals developing interventional strategies and programs to increase patients’ adherence rates in antidepressant treatment.
KeywordsMedication nonadherence Antidepressants Income Health insurance
- 20.McHorney CA, Spain VC, Alexander CM, Simmons J (2009) Validity of the adherence estimator in the prediction of 9-month persistence with medications prescribed for chronic diseases: a prospective analysis of data from pharmacy claims. Clin Ther 31(11):2584–2607. doi:10.1016/j.clinthera.2009.11.030 PubMedCrossRefGoogle Scholar
- 38.Fischer JF, Mowers RM, Ormerod DJ, Burris ES (2001) Driving market share in an integrated health system without therapeutic interchange. J Manag Care Pharm 7(4):283–286Google Scholar
- 39.Wang PS, Lane M, Olfson M, Pincus HA, Wells KB, Kessler RC (2005) Twelve-month use of mental health services in the United States: results from the national comorbidity survey replication. Arch Gen Psychiatry 62(6):624–629Google Scholar
- 43.Proctor BD, Dalaker J (2002) Current population reports. In: Poverty in the united states: 2001. US Government Printing Office, Washington, DCGoogle Scholar
- 46.American Psychiatric Association (2000) Practice guideline for the treatment of patients with major depression. American Psychiatric Association, ArlingtonGoogle Scholar
- 47.Robinson RL, Long SR, Chang S, Able S, Baser O, Obenchain RL, Swindle RW (2006) Higher costs and therapeutic factors associated with adherence to ncqa hedis antidepressant medication management measures: analysis of administrative claims. J Manag Care Pharmacy 12(1):43–54Google Scholar
- 48.Rush AJ, Trivedi MH, Wisniewski SR, Stewart JW, Nierenberg AA, Thase ME, Ritz L, Biggs MM, Warden D, Luther JF, Shores-Wilson K, Niederehe G, Fava M (2006) Bupropion-sr, sertraline, or venlafaxine-xr after failure of ssris for depression. N Engl J Med 354(12):1231–1242. doi:10.1056/NEJMoa052963 PubMedCrossRefGoogle Scholar
- 49.Kocsis JH, Schatzberg A, Rush AJ, Klein DN, Howland R, Gniwesch L, Davis SM, Harrison W (2002) Psychosocial outcomes following long-term, double-blind treatment of chronic depression with sertraline vs placebo. Arch Gen Psychiatry 59(8):723–728. doi:10.1001/archpsyc.59.8.723 PubMedCrossRefGoogle Scholar
- 50.Keller MB, Kocsis JH, Thase ME, Gelenberg AJ, Rush AJ, Koran L, Schatzberg A, Russell J, Hirschfeld R, Klein D, McCullough JP, Fawcett JA, Kornstein S, LaVange L, Harrison W, For the Sertraline Chronic Depression Study Group (1998) Maintenance phase efficacy of sertraline for chronic depression: a randomized controlled trial. JAMA 280(19):1665–1672. doi:10.1001/jama.280.19.1665 PubMedCrossRefGoogle Scholar
- 52.RTI International-University of North Carolina Evidence-based Practice Center (2007) Comparative effectiveness of second-generation antidepressants in the pharmacologic treatment of adult depression: comparative effectiveness review. Agency for Healthcare Research and Quality, RockvilleGoogle Scholar
- 56.Wu C-H, Erickson SR, Piette JD, Balkrishnan R. The association of race, comorbid anxiety, and antidepressant adherence among medicaid enrollees with major depressive disorder. ResSoc Adm Pharmacy. doi:10.1016/j.sapharm.2011.04.002
- 67.McLaughlin T, Hogue SL, Stang PE (2007) Once-daily bupropion associated with improved patient adherence compared with twice-daily bupropion in treatment of depression. American J Therapeutics 14 (2):221-225 210.1097/1001.mjt.0000208273.0000280496.0000208273fGoogle Scholar
- 72.Tamburrino MB, Nagel RW, Chahal MK, Lynch DJ (2009) Antidepressant medication adherence: a study of primary care patients. J Clin Psychiatry 11(5):205–211Google Scholar